Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes

被引:107
作者
Zehbe, I
Tachezy, R
Mytilineos, J
Voglino, G
Mikyskova, I
Delius, H
Marongiu, A
Gissmann, L
Wilander, E
Tommasino, M
机构
[1] Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany
[2] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic
[3] Heidelberg Univ, Dept Transplantat Immunol, D-6900 Heidelberg, Germany
[4] Osped Sant Anna, Serv Anat Patol, Turin, Italy
[5] Uppsala Univ, Dept Genet & Pathol, Uppsala, Sweden
关键词
HPV16; E6 and E7 genotypes; polymorphism; cervical lesion; human leukocyte antigen;
D O I
10.1002/ijc.1520
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Infection with high-risk human papillomavirus (HPV) is necessary for the development of a cervical lesion, but only a fraction of precursor lesions progress to cancer. Additional factors, other than HPV type per se, are likely to increase the probability for progression. Intratype genome variations have been reported to be associated with viral persistence and the development of a major cervical disease. We have recently shown that the prevalence of specific HPV16-E6 variants in invasive cervical cancer (ICC) varies between Italian and Swedish women. To extend our initial study we have analyzed E6 variants in cervical lesions from Czech women, ranging from low-grade cervical intraepithelial neoplasia (LCIN) to ICC and scaled up the sample size of our initial study of Swedish and Italian women. In addition, we have correlated the cases of cancers with human leukocyte antigen (HLA) class II haplotypes. In line with our earlier observation, the distribution of specific HPVI6-E6 genotypes in CIN and ICC varied in the 3 cohorts. For instance, the HPV16-E6 L83V variant, which has been found to be positively associated with ICC in Swedish women (p=0.002), was more prevalent in LCIN than in ICC in Italian and Czech women (p=0.01 and = 0.03, respectively). These data indicate that host genetic factors, such as HLA polymorphism, may determine the potential oncogenicity of the HPVI6-E6 L83V variant. Indeed, the DR04-DQ03 haplotype, which is approximately 3-fold more abundant in the normal Swedish population than in those in Italy and the Czech Republic, was found to be positively associated with HPVI6-E6 L83V in the 3 cohorts investigated (p=0.01). This observation may explain why L83V is a risk factor more in Sweden than in the other 2 countries. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:711 / 716
页数:6
相关论文
共 33 条
  • [1] HLA DQ-DR haplotype and susceptibility to cervical carcinoma: Indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18
    Allen, M
    Kalantari, M
    Ylitalo, N
    Pettersson, B
    Hagmar, B
    Scheibenpflug, L
    Johansson, B
    Petterson, U
    Gyllensten, U
    [J]. TISSUE ANTIGENS, 1996, 48 (01): : 32 - 37
  • [2] Bontkes HJ, 1998, INT J CANCER, V78, P166, DOI 10.1002/(SICI)1097-0215(19981005)78:2<166::AID-IJC8>3.0.CO
  • [3] 2-X
  • [4] Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters
    Brady, CS
    Duggan-Keen, MF
    Davidson, JA
    Varley, JM
    Stern, PL
    [J]. JOURNAL OF GENERAL VIROLOGY, 1999, 80 : 3233 - 3240
  • [5] Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women
    Cuzick J.
    Terry G.
    Ho L.
    Monaghan J.
    Lopes A.
    Clarkson P.
    Duncan I.
    [J]. British Journal of Cancer, 2000, 82 (7) : 1348 - 1352
  • [6] VIRUSES IN HUMAN CANCERS
    HAUSEN, HZ
    [J]. SCIENCE, 1991, 254 (5035) : 1167 - 1173
  • [7] HELLAND A, 1994, CANCER EPIDEM BIOMAR, V3, P479
  • [8] Human papillomavirus type 16 variants and risk of cervical cancer
    Hildesheim, A
    Schiffman, M
    Bromley, C
    Wacholder, S
    Herrero, R
    Rodriguez, AC
    Bratti, MC
    Sherman, ME
    Scarpidis, U
    Lin, QQ
    Terai, M
    Bromley, RL
    Buetow, K
    Apple, RJ
    Burk, RD
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04): : 315 - 318
  • [9] IMANISKI T, 1992, HLA 1991 P 11 INT HI, V1
  • [10] Londesborough P, 1996, INT J CANCER, V69, P364